PTGS2 and rectum adenocarcinoma: Konturek et al. reported that a 14-day therapy with celecoxib, inhibitor of cyclooxygenase-2, lead to a significant decrease of survivin in tumour tissue and normal rectal mucosa of patients with rectal adenocarcinoma [29].